Literature DB >> 3210846

[Effect of serial CEA determination on diagnosis, therapy and prognosis of recurrent colorectal cancer].

B Mentges1.   

Abstract

A rising CEA level did not indicate an early tumour recurrence in the follow-up of 660 patients with curative surgery because of colorectal carcinoma. In case of rectal carcinoma the first rise of the tumour marker preceded diagnosis of recurrence by other means 7.9 months on an average, in case of colonic carcinoma 5.1 months. The long-term survival after secondary procedure was 17.5% for patients with normal CEA value at time of reoperation and surmounted life expectancy of patients with rising tumour-marker level significantly (5.9%). The worst prognosis was found for the collective with rising CEA before diagnosis of relapse by other means, none of whom was saved by reoperation. The resectability rate of metastases was higher than that of local recurrences with nearly identical survival for both groups. Because of the long CEA lead times advances in therapy by second-look procedures are to be expected mainly for patients with pelvic recurrences after abdominoperineal extirpation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3210846     DOI: 10.1007/bf01261814

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  22 in total

1.  Monitoring of patients with carcinoma of the large intestine by use of acute phase proteins and carcinoembryonic antigen.

Authors:  B N Gray; C Walker
Journal:  Surg Gynecol Obstet       Date:  1983-06

2.  Pre- and postoperative uses of CEA.

Authors:  J T Evans; A Mittelman; M Chu; E D Holyoke
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

3.  Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer.

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Am J Surg       Date:  1978-09       Impact factor: 2.565

4.  Serum CEA monitoring in the follow-up of colorectal cancer patients with negative preoperative serum CEA.

Authors:  G Mariani; M Carmellini; F Bonaguidi; M A Benelli; M G Toni
Journal:  Eur J Cancer       Date:  1980-08       Impact factor: 9.162

5.  CEA as a monitor of gastrointestinal malignancy.

Authors:  E D Holyoke; T M Chu; G P Murphy
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

6.  [Prospective follow-up study of radically resected colorectal carcinoma. Status after 5 years].

Authors:  U Metzger; K Bronz; H Bühler; A Dolder; U Seefeld; A Hollinger; F Largiadèr
Journal:  Schweiz Med Wochenschr       Date:  1985-07-20

7.  The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures.

Authors:  E W Martin; K K James; P E Hurtubise; P Catalano; J P Minton
Journal:  Cancer       Date:  1977-02       Impact factor: 6.860

8.  Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma.

Authors:  J J Szymendera; M P Nowacki; A W Szawłowski; J A Kamińska
Journal:  Dis Colon Rectum       Date:  1982 Jan-Feb       Impact factor: 4.585

9.  [Key role of the CEA test in the diagnosis and surgical therapy of recurrent colorectal cancer].

Authors:  A Quentmeier; P Schlag; C Herfarth
Journal:  Chirurg       Date:  1986-02       Impact factor: 0.955

10.  Value of serial carcinoembryonic antigen determinations for early detection of recurrent cancer.

Authors:  B N Gray; C Walker; R Barnard
Journal:  Med J Aust       Date:  1981-02-21       Impact factor: 7.738

View more
  2 in total

1.  Ultrasonic endoluminal examination in the follow-up of colorectal cancer. Initial experience and results.

Authors:  K Dresing; W Stock
Journal:  Int J Colorectal Dis       Date:  1990-12       Impact factor: 2.571

Review 2.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.